The purpose of this study is to observe the number of new cases of infections per population in a given time period and their characteristics in a pathology (myelodysplastic syndrome, MDS)that involves ineffective production (or dysplasia) of a class of blood cells.
The scarcity and the inadequacy of data make impossible the writing of evidence-based recommendations for prevention and management of infections in myelodysplastic syndrome. The aim of this study is to evaluate the incidence and the spectrum of the infections of MDS patients. Will be also evaluated potential risk factors. This study could help the definition of the optimal management of MDS patients in terms of prophylaxis of the infective complications and in terms of the correct administration of growth factors.
Study Type
OBSERVATIONAL
Enrollment
229
Number of infectious events in myelodysplastic syndrome patients
Infectious events are fungal and antibiotic events
Time frame: at 1 year from study entry
Number of MDS patients with a febrile event treated with antibiotic, antifungal and antiviral therapy
Time frame: at 1 year from study entry
Level of neutropenia
Time frame: at 1 year from study entry
Number of patients who recover from infection
Time frame: at 1 year from study entry
Number of patients recovered from infection out of the total of patients with documented infection during the observational period
Time frame: at 1 year from study entry
Number of patients who don't develop bacterial infection
Time frame: at 1 year from study entry
Number of patient who don't develop fungal infection
Time frame: at 1 year from study entry
Number of patient who don't develop viral infection
Time frame: at 1 year from study entry
Number of patients that needed granulocyte growth factors
Time frame: at 1 year from study entry
Number of patients that needed iron sequestrating therapy caused by iron overload
Time frame: at 1 year from study entry
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo
Alessandria, Italy
Azienda Ospedaliera - Nuovo Ospedale 'Torrette'
Ancona, Italy
UO Ematologia con trapianto-Università degli Studi di Bari Aldo Moro
Bari, Italy
Divisione di Ematologia Ospedale A. Perrin
Brindisi, Italy
ASL N.8 - Ospedale "A. Businco" - Struttura Complessa di Ematologia e CTMO
Cagliari, Italy
Policlinico di Careggi
Florence, Italy
IRCCS_AOU San Martino-IST-Ematologia 1-Monoblocco 11°piano- lato ponente
Genova, Italy
ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE
Lecce, Italy
Azienda Ospedaliera Universitaria - Università degli Studi di Napoli "Federico II" - Facoltà di Medicina e Chirurgia
Napoli, Italy
S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro
Novara, Italy
...and 15 more locations
Length of the hospitalization
Time frame: at 1 year from study entry
Weeks of MDS suspension treatment
Time frame: at 1 year from study entry
Number of patients responding to therapy according to the administered treatment
Time frame: at 1 year from study entry
Number of MDS patients alive
Time frame: at 1 year from study entry
Number of patients without MDS progression
Time frame: at 1 year from study entry
Need for hospitalization
Time frame: at 1 year from study entry
Level transfusion dependence
Time frame: At one year from study entry
Level of MDS subtype
Time frame: At one year from study entry
Level of risk of International Prognostic Scoring System (IPSS)
Time frame: At one year from study entry
Level of International Prognostic Scoring System (IPSS)-revised
Time frame: At one year from study entry
Level of iron overload
Time frame: At one year from study entry.